Search

iRhythm Technologies Inc

Suletud

SektorTervishoid

111.2 0.69

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

108.41

Max

112.85

Põhinäitajad

By Trading Economics

Sissetulek

-20M

-14M

Müük

-9.5M

199M

Aktsiakasum

-0.35

Kasumimarginaal

-6.988

Töötajad

2,400

EBITDA

-20M

-3.6M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+57.9% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

6. aug 2026

Turustatistika

By TradingEconomics

Turukapital

-322M

3.8B

Eelmine avamishind

110.51

Eelmine sulgemishind

111.2

Uudiste sentiment

By Acuity

69%

31%

303 / 340 Pingereas Healthcare

iRhythm Technologies Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. juuli 2026, 19:16 UTC

iRhythm Technologies Inc is trading higher Monday, having reached a peak cumulative return earlier in the session. No specific news was identified to explain the movement.

Võrdlus sarnastega

Hinnamuutus

iRhythm Technologies Inc Prognoos

Hinnasiht

By TipRanks

57.9% tõus

12 kuu keskmine prognoos

Keskmine 175.08 USD  57.9%

Kõrge 255 USD

Madal 147 USD

Põhineb 13 Wall Streeti analüütiku instrumendi iRhythm Technologies Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

12

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

303 / 340 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest iRhythm Technologies Inc

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
help-icon Live chat